After Today's Big Increase, Is Clovis Oncology, Inc. (CLVS)'s Near-Term Analysis Positive?

Lloyd Doyle
December 7, 2017

Analyzing the last five market sessions, the stock was able to report -2.17% losses, thus going down by -17.36%, compared with its 200-day moving average of $74.8. Lord Abbett & Ltd Liability Company, a New Jersey-based fund reported 579,397 shares. (NASDAQ:CLVS). Wexford Cap Lp has invested 0.03% of its portfolio in Clovis Oncology, Inc. About 762,477 shares traded.

Clovis Oncology, Inc. (CLVS) has so far tried but failed to beat the consensus-estimated -$1.22, with their earning staying at -$1.24 per share. State Street Corp now owns 1,943,480 shares of the biopharmaceutical company's stock valued at $181,966,000 after purchasing an additional 80,171 shares during the period. Following the sale, the insider now directly owns 191,583 shares in the company, valued at $13,315,018.50.

The stock decreased 0.10% or $0.05 during the last trading session, reaching $51.15. Its up 35.8% from 41.13M shares previously. Therefore 70% are positive. Royal Bank Of Canada assumed coverage on shares of Clovis Oncology in a report on Thursday, September 14th.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other worldwide markets. (NASDAQ:CLVS) to report earnings on February, 28. Chardan Capital Markets has "Sell" rating and $15 target. Finally, Stifel Nicolaus reissued a "buy" rating and set a $125.00 price objective on shares of Clovis Oncology in a report on Friday, November 3rd. (NASDAQ:CLVS) rating on Monday, November 16. Morgan Stanley invested 0% in FCB Financial Holdings, Inc.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) has "Hold" rating given on Wednesday, December 21 by WallachBeth Capital. Oppenheimer maintained the stock with "Hold" rating in Monday, July 31 report.

Investors sentiment decreased to 1.81 in Q2 2017.

Esperion Therapeutics, Inc. analysts gave 6 buy-equivalent recommendations, 0 sells and 2 holds.


According to 14 stock analysts, Clovis Oncology, Inc., is being kept at an average Outperform, rating, with at least 14.65% of shares outstanding that are now legally short sold. Vanguard Group Inc. raised its stake in shares of Clovis Oncology by 10.2% during the 2nd quarter. Greenwood Capital Assocs Ltd Liability Corporation holds 55,486 shares or 0.08% of its portfolio. (NASDAQ:CLVS). Hanseatic Mngmt invested in 0.65% or 13,693 shares.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other worldwide markets. (NASDAQ:CLVS). Nationwide Fund Advsrs reported 117,428 shares or 0.04% of all its holdings.

In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the business's stock in a transaction that occurred on Monday, October 16th. California Public Employees Retirement System lifted its position in Clovis Oncology by 11.7% during the third quarter. Bourgeon Mngmt Lc holds 0.53% of its portfolio in Clovis Oncology, Inc. Rice Hall James And Associates invested in 0.51% or 126,413 shares. Bain Cap Pub Equity Llc owns 0.79% invested in Clovis Oncology, Inc. Sivik Global Healthcare Ltd Liability Com accumulated 20,000 shares. (NASDAQ:CLVS). Sabby Mngmt Ltd Company owns 7,065 shares or 0.04% of their U.S. portfolio.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. (NASDAQ:CLVS). 32,800 were accumulated by Dekabank Deutsche Girozentrale. 42,309 were reported by Kennedy Mgmt. Creative Planning reported 0% stake. During the same quarter in the previous year, the business earned ($1.70) EPS. equities research analysts anticipate that Clovis Oncology will post -7.63 EPS for the current year. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($1.18) by ($0.06). Piper Jaffray reinitiated Clovis Oncology, Inc. TherapeuticsMD, Inc. (NASDAQ:TXMD) has declined 46.30% since December 6, 2016 and is downtrending. Businesswire.com's news article titled: "Clovis Oncology to Present at the Stifel 2017 Healthcare Conference" with publication date: November 08, 2017 was also an interesting one.

Addison Clark Management Llc, which manages about $1.74B and $69.47M US Long portfolio, decreased its stake in Penn Natl Gaming Inc (NASDAQ:PENN) by 207,480 shares to 120,571 shares, valued at $2.58M in 2017Q2, according to the filing. (NASDAQ:CLVS) for 63,709 shares.

Among 4 analysts covering Bravo Brio Restaurant Group Inc. Cubist Systematic Strategies Limited Com reported 0% stake. WallachBeth Capital downgraded the shares of CLVS in report on Tuesday, November 17 to "Hold" rating. The company was initiated on Thursday, January 21 by Credit Suisse. Jefferies maintained Bravo Brio Restaurant Group, Inc. The firm has "Buy" rating by SunTrust given on Wednesday, August 24.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER